What is the 13F Pro Quality Score for HUM?

13F Pro ranks HUMANA INC (HUM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HUM's current score at https://13fpro.ai/company/HUM (free sign-up required for the full ranking).

Which hedge funds own the most HUM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of HUM include DODGE & COX, BlackRock,, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/HUM as soon as new 13F filings post.

Where does 13F Pro source HUM data?

All HUMANA INC fundamentals and ownership data come directly from SEC EDGAR. HUMANA INC files with the SEC under CIK 49071. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HUM in?

HUMANA INC (HUM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives HUM's revenue?

Per HUMANA INC's latest 10-Q filed with the SEC on 2026-07-29, the biggest revenue drivers are: Insurance segment ($39.0B, +26.2% YoY); Individual Medicare Advantage ($28.9B, +26.8% YoY); Medicare stand-alone PDP ($3.0B, +74.0% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/HUM.

What are HUM's largest expenses?

HUMANA INC's latest 10-Q reports these as the largest expense items: Benefits expense ($35.4B, +28.3% YoY); Operating costs ($4.0B, +12.2% YoY); Depreciation and amortization ($159M, -10.7% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is HUM research updated on 13F Pro?

HUM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

HUMANA INC(HUM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 49071 HUM stock profile & AI dashboard →

13F Pro Quality Score

58.9/100

Rank #966 of 2,960 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

65.6/100

Profitability

35.4/100

Balance Sheet

54.9/100

Earnings Quality

74.7/100

Free Cash Flow

29.2/100

Institutional Flow

64.0/100

Revenue Scale

98.9/100

Dilution Risk

85.8/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why HUM Scores 59/100

exact factor attribution · 2026-09-10

HUM's composite is driven by scale and revenue growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+7.3 pts

99th pct

Revenue growth

+3.1 pts

66th pct

Earnings quality

+2.5 pts

75th pct

Shareholder dilution

+1.8 pts

86th pct

Institutional flow

+0.7 pts

64th pct

Capital efficiency

+0.5 pts

55th pct

Earnings growth

-1.7 pts

16th pct

Profitability

-2.2 pts

35th pct

Free cash flow

-3.1 pts

29th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

HUM Stock Analysis & AI Quality Score

Data updated 2026-09-10

AI stock analysis and institutional research for HUMANA INC (HUM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HUM at 58.9/100 on a 32-signal composite quality model, placing it at rank #966 of 2,960 stocks — the top half of the AI-ranked universe. HUM scores in the top quartile across revenue scale (98.9). Areas of concern include free cash flow (29.2) and profitability (35.4), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), HUMANA INC reports quarterly revenue of $39.6B, net income of $1.2B, an operating margin of 4.4%. Top institutional holders of HUM by reported 13-F value include DODGE & COX, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. HUM trades on the NYSE exchange and files with the SEC under CIK 49071. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HUM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HUMANA INC directly from SEC EDGAR. HUMANA INC's 13F Pro composite quality score has ranged between 59 and 76 since 2021, currently 58.9 — a declining long-term trajectory across 67 quarterly and live scoring snapshots.

✦

Fun facts about HUMANA INC

Quirks, history, and lore behind HUM — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · large-cap · listed on the NYSE · headquartered in Kentucky.
2
The Numbers
Annual revenue north of $100 billion, with roughly 40 million members enrolled across its health plans — one of the largest such pools in the country.
3
The History
Founded in 1961, it started life as a nursing home company before pivoting hard into health insurance — one of the more dramatic identity changes in corporate history.
4
The Secret
Its business is heavily concentrated in Medicare Advantage — government-funded plans for seniors — making it uniquely exposed to federal reimbursement rates every time Washington sneezes.
5
The Lore
It owns a constellation of primary care clinics and a pharmacy benefits operation, making it less an insurer and more a vertically integrated health empire — whether patients notice or not.
6
The Giveaway
Its ticker is three letters that sound like a friendly greeting, its logo is a friendly green swoosh, and it is the dominant Medicare Advantage insurer in the United States.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving HUM's Business? Latest 10-Q Breakdown

✓ 30/30 datapoints verified

AI-extracted from HUMANA INC's 10-Q filed 2026-07-29 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Humana grew Q2 revenue 26.2% YoY to $40.9B on Medicare membership gains, but the benefit ratio rose 140bps to 91.1% on Star Ratings headwinds and lower favorable reserve development.

Biggest Revenue Drivers

Insurance segment$39.0B+26.2% YoY

Membership growth across Medicare businesses, higher per-member MA and PDP premiums from increased CMS benchmark funding and IRA-driven Part D subsidy, partly offset by BY2026 Star Ratings headwind

CenterWell segment$1.6B+32.4% YoY

Continued expansion of payor-agnostic client base, primarily in primary care, partly offset by phase-in of the v28 risk model revision

Biggest Revenue Drivers

Total revenue: $40.9B+26.2% YoY

Insurance segment$39.0B+26.2% YoY

Membership growth across Medicare businesses, higher per-member MA and PDP premiums from increased CMS benchmark funding and IRA-driven Part D subsidy, partly offset by BY2026 Star Ratings headwind

Within Insurance segment

Individual Medicare Advantage$28.9B+26.8% YoY

Net membership gains during the most recent AEP and OEP

Medicare stand-alone PDP$3.0B+74.0% YoY

Membership additions from group MA recontracting efforts and the 2026 selling season

CenterWell segment$1.6B+32.4% YoY

Continued expansion of payor-agnostic client base, primarily in primary care, partly offset by phase-in of the v28 risk model revision

Within CenterWell segment

Primary care$839M+63.5% YoY

Growth from recent acquisitions

Largest Expense Items

Benefits expense$35.4B+28.3% YoY

BY2026 Star Ratings revenue headwind, higher benefit ratio on new individual MA members vs. retained members, and anticipated lower favorable prior-period claims reserve development

Operating costs$4.0B+12.2% YoY

Higher charges from value creation/transformation initiatives ($56M in Q2), partly offset by operating leverage from membership growth and administrative cost efficiencies

Depreciation and amortization$159M-10.7% YoY

Decreased capital spending

Interest expense$197M+25.5% YoY

Financing costs including liquidity/capital management measures and higher average debt balances

Margins: Consolidated benefit ratio rose 140bps YoY to 91.1% on the BY2026 Star Ratings headwind, a richer benefit ratio among new AEP/OEP members, and lower favorable prior-period reserve development, while the operating cost ratio improved 120bps to 9.8% on operating leverage and cost-cutting initiatives.

Watch Items from the Filing

Medicare products (Medicare Advantage and Part D) represented approximately 86% of total premiums and services revenue for the six months ended June 30, 2026, concentrating the company in a single, heavily regulated federal contract relationship.
RADV audit litigation is ongoing: a district court vacated CMS's Final RADV Rule in September 2025, but the government has appealed to the Fifth Circuit, leaving uncertainty over risk-adjustment audit methodology and potential recoveries.
Put option liability tied to the Welsh, Carson, Anderson & Stowe primary care partnership was valued at $1.6 billion at June 30, 2026, up from $1.4 billion at year-end 2025, with fair-value swings running through Other expense.
Short-term debt jumped to $2.3 billion at June 30, 2026 from zero at year-end 2025, including $1.3 billion of commercial paper and a $1.0 billion junior subordinated notes issuance in March 2026, alongside a new $750M P-Cap on-demand capital arrangement.
Ongoing securities class action (In re Humana Inc. Securities Litigation), shareholder derivative suits, and a DOJ-intervened qui tam suit (eHealth) allege misstatements about medical costs, Star Ratings, and broker distribution relationships.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$39.6B

Net Income

Q1 2026

$1.2B

Free Cash Flow

Q1 2026

$1.1B

Operating Margin

Q1 2026

4.4%

ROIC

Q1 2026

21.5%

D/E Ratio

Q1 2026

0.75

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+10.1% YoY

$129.66BFY 2025

FY22 $92.87BFY23 $106.37BFY24 $117.76BFY25 $129.66B

Net Income

-1.6% YoY

$1.19BFY 2025

FY22 $2.81BFY23 $2.49BFY24 $1.21BFY25 $1.19B

Operating Income

+5.5% YoY

$2.70BFY 2025

FY22 $3.80BFY23 $4.01BFY24 $2.56BFY25 $2.70B

EPS (Diluted)

-1.4% YoY

$9.84FY 2025

FY22 $22.08FY23 $20.00FY24 $9.98FY25 $9.84

Total Assets

+5.2% YoY

$48.91BFY 2025

FY22 $43.05BFY23 $47.06BFY24 $46.48BFY25 $48.91B

Total Debt

+5.5% YoY

$12.37BFY 2025

FY22 $11.13BFY23 $11.66BFY24 $11.72BFY25 $12.37B

Op. Cash Flow

-68.9% YoY

$921.0MFY 2025

FY22 $4.59BFY23 $3.98BFY24 $2.97BFY25 $921.0M

Free Cash Flow

-84.3% YoY

$375.0MFY 2025

FY22 $3.45BFY23 $2.98BFY24 $2.39BFY25 $375.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$129.66B +10.1%	$117.76B +10.7%	$106.37B +14.5%	$92.87B +11.8%	$83.06B +7.7%	$77.16B
Net Income	$1.19B -1.6%	$1.21B -51.5%	$2.49B -11.3%	$2.81B -4.3%	$2.93B -12.9%	$3.37B
Operating Income	$2.70B +5.5%	$2.56B -36.2%	$4.01B +5.6%	$3.80B +20.7%	$3.15B -36.9%	$4.99B
EPS (Diluted)	$9.84 -1.4%	$9.98 -50.1%	$20.00 -9.4%	$22.08 -2.6%	$22.67 -10.4%	$25.31
Total Assets	$48.91B +5.2%	$46.48B -1.2%	$47.06B +9.3%	$43.05B -2.9%	$44.36B +26.8%	$34.97B
Total Debt	$12.37B +5.5%	$11.72B +0.6%	$11.66B +4.8%	$11.13B -10.9%	$12.49B +87.6%	$6.66B
Operating Cash Flow	$921.0M -68.9%	$2.97B -25.5%	$3.98B -13.2%	$4.59B +102.8%	$2.26B -59.9%	$5.64B
Free Cash Flow	$375.0M -84.3%	$2.39B -19.7%	$2.98B -13.7%	$3.45B +275.0%	$920.0M -80.3%	$4.67B

AI Insight: HUM Financial Trends

Q1 2026 revenue surged 24% YoY to $39.6B, but operating performance remains volatile with cyclical seasonal swings masking underlying profitability pressure.

• Q1 2026 revenue jumped to $39.6B, up 24% from $32.1B in Q1 2025; operating income recovered to $1.75B after Q4 2025 loss of $808M.

• Operating cash flow swung from negative $1.65B in Q4 2025 to positive $1.25B in Q1 2026, signaling seasonal working capital normalization.

• Equity strengthened to $18.6B in Q1 2026 from $17.7B in Q4 2025; debt rose to $14.0B, increasing leverage ratio to 0.75x.

⚠ Net income volatility persists: Q1 2026 shows $1.2B profit, but Q3–Q4 2025 collapsed to near-zero earnings despite flat revenue—underlying margin stress.

⚠ Q4 2025 operating loss of $808M on $32.5B revenue marks second consecutive seasonal trough; watch if Q2–Q3 2026 repeat pattern.

AI Insight: HUM Ratio Trends

Humana's profitability metrics are deeply depressed on a trailing-twelve-month basis, with OpMargin at 1.8% and ROA at 2.0%, reflecting severe Q4 2025 losses that offset modest Q1 2026 recovery.

• Q4 2024 and Q4 2025 both posted significant losses (OpMargin -1.9% and -2.5% respectively), suggesting structural seasonal headwinds or recurring Q4 pressures.

• Q1 2026 operating margin improved to 4.4% from Q3 2025's 1.3%, with ROIC rebounding to 21.5%; quarterly pattern mirrors Q1 2025's 6.3% OpMargin spike.

• Leverage stable: D/E ratio ranged 0.68–0.77 across all periods, ending Q1 2026 at 0.75, showing balanced debt management amid earnings volatility.

⚠ TTM profitability collapsed versus prior-year TTM: Q2 2024 OpMargin was 4.0%; current TTM stands at 1.8%, driven by two back-to-back negative Q4s.

⚠ Sequential volatility extreme: ROIC swung from 25.9% (Q1 2025) to -7.7% (Q4 2024) to -10.8% (Q4 2025), indicating unpredictable earnings or accounting drivers.

Get alerted when HUM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for HUMANA INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HUM

DODGE & COX
$4.3B10,940,380 sh
BlackRock, Inc.
$4.1B10,417,803 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.1B7,843,620 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.3B5,818,956 sh
STATE STREET CORP
$2.2B5,457,072 sh
PZENA INVESTMENT MANAGEMENT LLC
$1.7B4,403,136 sh
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$1.7B3,578,245 sh
EAGLE CAPITAL MANAGEMENT LLC
$1.5B3,846,762 sh
Sessa Capital IM, L.P.
$1.5B3,727,740 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.3B3,369,757 sh

Fund	Value	Shares
DODGE & COX	$4.3B	10,940,380
BlackRock, Inc.	$4.1B	10,417,803
VANGUARD CAPITAL MANAGEMENT LLC	$3.1B	7,843,620
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.3B	5,818,956
STATE STREET CORP	$2.2B	5,457,072
PZENA INVESTMENT MANAGEMENT LLC	$1.7B	4,403,136
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$1.7B	3,578,245
EAGLE CAPITAL MANAGEMENT LLC	$1.5B	3,846,762
Sessa Capital IM, L.P.	$1.5B	3,727,740
GEODE CAPITAL MANAGEMENT, LLC	$1.3B	3,369,757

Companies Similar to HUM

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ELV

Elevance Health, Inc.

AI score

Very similar · 38 shared holders

EAGLE CAPITAL MANAGEMENT LLC Newport Trust Company, LLC HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC

CNC

CENTENE CORP

AI score

Very similar · 38 shared holders

HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC GLENVIEW CAPITAL MANAGEMENT, LLC Maple Rock Capital Partners Inc.

CVS

CVS HEALTH Corp

AI score

Very similar · 40 shared holders

DODGE & COX PZENA INVESTMENT MANAGEMENT LLC Capital International Investors

UNH

UNITEDHEALTH GROUP INC

AI score

Very similar · 36 shared holders

DODGE & COX EAGLE CAPITAL MANAGEMENT LLC Capital International Investors

BDX

BECTON DICKINSON & CO

AI score

Similar quality profile · 29 shared holders

1832 Asset Management L.P.National Pension Service abrdn plc

MDLN

Medline Inc.

AI score

Similar quality profile · 23 shared holders

Capital Research Global Investors National Pension Service Capital World Investors

IQV

IQVIA HOLDINGS INC.

AI score

Shared smart-money ownership · 22 shared holders

1832 Asset Management L.P.National Pension Service Capital World Investors

GEHC

GE HealthCare Technologies Inc.

AI score

Shared smart-money ownership · 41 shared holders

DODGE & COX HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC BARROW HANLEY MEWHINNEY & STRAUSS LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HUM on your watchlist

Track score changes the day HUMANA INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HUM a good stock to buy?

13F Pro's AI-powered analysis of HUMANA INC (HUM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HUM are available on the HUM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. HUM is classified as a large company.

Which hedge funds own HUM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HUM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of HUMANA INC's investment landscape.